Guggenheim Reiterates Buy on Zentalis Pharma, Maintains $6 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 82.4%

Neg 0% Neu 82.4% Pos 0%

Guggenheim analyst Michael Schmidt reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Buy and maintains $6 price target.

Comments

No comments yet. Be the first!